Zoetis (ZTS) Income towards Parent Company (2012 - 2026)
Zoetis (ZTS) posted quarterly Income towards Parent Company of $601.0 million for Q1 2026, little changed year-over-year from $602.0 million in Q1 2025, and little changed quarter-over-quarter from $603.0 million in Q4 2025.
Zoetis (ZTS) Income towards Parent Company (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Income towards Parent Company for 15 consecutive years, with $601.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company changed 0.17% year-over-year to $601.0 million; the TTM figure through Mar 2026 stood at $2.6 billion (up 5.76% YoY), while the FY2025 annual figure was $2.7 billion, up 7.09% from the prior year.
- Income towards Parent Company was little changed at $601.0 million in Q1 2026 per ZTS's latest filing, from $603.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $721.0 million in Q3 2025 and bottomed at $460.0 million in Q4 2022.
- Historically, Income towards Parent Company has averaged $599.5 million across 5 years, with a median of $599.0 million in 2024.
- On a YoY basis, Income towards Parent Company climbed as much as 26.65% in 2023 and fell as far as 7.24% in 2023.
- Zoetis' Income towards Parent Company stood at $460.0 million in 2022, then advanced by 13.7% to $523.0 million in 2023, then increased by 11.09% to $581.0 million in 2024, then advanced by 3.79% to $603.0 million in 2025, then declined by 0.33% to $601.0 million in 2026.
- Business Quant data shows ZTS's Income towards Parent Company at $601.0 million in Q1 2026, $603.0 million in Q4 2025, and $721.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 691.00 Mn |
| Mar 31, 2026 | 601.00 Mn |
| Dec 31, 2025 | 603.00 Mn |
| Sep 30, 2025 | 721.00 Mn |
| Jun 30, 2025 | 718.00 Mn |
| Mar 31, 2025 | 602.00 Mn |
| Dec 31, 2024 | 581.00 Mn |
| Sep 30, 2024 | 692.00 Mn |
| Jun 30, 2024 | 624.00 Mn |
| Mar 31, 2024 | 599.00 Mn |
| Dec 31, 2023 | 523.00 Mn |
| Sep 30, 2023 | 596.00 Mn |
| Jun 30, 2023 | 670.00 Mn |
| Mar 31, 2023 | 551.00 Mn |
| Dec 31, 2022 | 460.00 Mn |
| Sep 30, 2022 | 528.00 Mn |
| Jun 30, 2022 | 529.00 Mn |
| Mar 31, 2022 | 594.00 Mn |
| Dec 31, 2021 | 413.00 Mn |
| Sep 30, 2021 | 552.00 Mn |